TGFB1 and neoplasm: The most frequently cited article is “Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TANs” (Fridlender, ZG, et al., 2009) (2220) (7) (39), which focuses on how TGF-β blockers alter the phenotype of tumor-associated neutrophils (TANs) from a pro-tumorigenic “N2” phenotype to an anti-tumorigenic “N1” phenotype, which slows tumor growth and enhance the activation of CD8+ T cells.